EGFR and non-small cell lung carcinoma: It has been reported that EGFR-TKI therapy results in a 56%–89% ORR at intracranial sites, a median PFS of 6.6 to 15.2 months and a median OS of 12.9 to 19.8 months in EGFR mutation-positive NSCLC patients with brain metastasis [30].